Netherlands· NL-fd15c90c6114
MYQORZO 15 mg filmomhulde tabletten
A medicinal product containing aficamten, registered in Netherlands by Cytokinetics (Ireland) Limited.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- AFICAMTEN
- Manufacturer
- Cytokinetics (Ireland) Limited
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/2014
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aficamten in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumMyqorzo 15 mgCytokinetics (Ireland) Limited
- CzechiaMYQORZOCytokinetics (Ireland) Limited, Dublin
- SpainMYQORZO 15 MG COMPRIMIDOS RECUBIERTOS CON PELICULACytokinetics (Ireland) Limited
- FinlandMYQORZOCytokinetics (Ireland) Limited
- IrelandMYQORZO 15 mg film-coated tabletsCytokinetics (Ireland) Limited
- IcelandMyQorzoCytokinetics (Ireland) Limited
- PolandMyqorzoCytokinetics (Ireland) Limited
- SwedenMYQORZO 15 mg Filmdragerad tablettCytokinetics (Ireland) Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5e688cf1-018d-46c5-9270-5c30d3b9232d GET /v1/drugs/5e688cf1-018d-46c5-9270-5c30d3b9232d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/myqorzo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134382",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"COPOLYMEER VAN MACROGOL (25,0)-POLY(VINYL ALCOHOL) (75,0) (E 1209)",
"CROSCARMELLOSE NATRIUM (E 468)",
"GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
"HYPROLOSE (E 463)",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"KARMIJN (E120)",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMLAURILSULFAAT",
"POLYVINYLALCOHOL (E 1203)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"AFICAMTEN"
],
"leaflet_url": null,
"authorised_at": "2026/02/12",
"procedure_number": "EMEA/H/C/006228",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/2014",
"additional_monitoring": "Y"
}See everything about aficamten.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.